ABSTRACT
Equid alphaherpesvirus 1 (EqAHV1) is a viral pathogen known to cause respiratory disease, neurologic syndromes, and abortion storms in horses. Currently, there are no vaccines that provide complete protection against EqAHV1. Marker vaccines and the differentiation of infected and vaccinated animals (DIVA) strategy are effective for preventing and controlling outbreaks but have not been used for the prevention of EqAHV1 infection. Glycoprotein 2 (gp2), located on the envelope of viruses (EqAHV1), exhibits high antigenicity and functions as a molecular marker for DIVA. In this study, a series of EqAHV1 mutants with deletion of gp2 along with other virulence genes (TK, UL24/TK, gI/gE) were engineered. The mutant viruses were studied in vitro and then in an in vivo experiment using Golden Syrian hamsters to assess the extent of viral attenuation and the immune response elicited by the mutant viruses in comparison to the wild-type (WT) virus. Compared with the WT strain, the YM2019 Δgp2, ΔTK/gp2, and ΔUL24/TK/gp2 strains exhibited reduced growth in RK-13 cells, while the ΔgI/gE/gp2 strain exhibited significantly impaired proliferation. The YM2019 Δgp2 strain induced clinical signs and mortality in hamsters. In contrast, the YM2019 ΔTK/gp2 and ΔUL24/TK/gp2 variants displayed diminished pathogenicity, causing no observable clinical signs or fatalities. Immunization with nasal vaccines containing YM2019 ΔTK/gp2 and ΔUL24/TK/gp2 elicited a robust immune response in hamsters. In particular, compared with the vaccine containing the ΔTK/gp2 strain, the vaccine containing the ΔUL24/TK/gp2 strain demonstrated enhanced immune protection upon challenge with the WT virus. Furthermore, an ELISA for gp2 was established and refined to accurately differentiate between infected and vaccinated animals. These results confirm that the ΔUL24/TK/gp2 strain is a safe and effective live attenuated vaccine candidate for controlling EqAHV1 infection.
Subject(s)
Herpesviridae Infections , Herpesvirus 1, Equid , Vaccines, Attenuated , Animals , Vaccines, Attenuated/immunology , Herpesviridae Infections/prevention & control , Herpesviridae Infections/immunology , Herpesviridae Infections/virology , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/immunology , Herpesvirus 1, Equid/genetics , Horses , Mesocricetus , Antibodies, Viral/blood , Antibodies, Viral/immunology , Viral Envelope Proteins/immunology , Viral Envelope Proteins/genetics , Cricetinae , Horse Diseases/prevention & control , Horse Diseases/immunology , Horse Diseases/virology , Viral Vaccines/immunology , Viral Vaccines/genetics , Cell Line , MutationABSTRACT
Equid alphaherpesvirus 1 (EHV-1) is prevalent in China, and causes notable economic damage to the equine industry. However, there is no information regarding the molecular characteristics and pathogenicity of the Chinese strains. Therefore, an EHV-1 strain, named YM2019, was isolated from the lung tissue of an aborted horse fetus in Xinjiang, China, and its genome and pathogenicity were analyzed. The full genome of the isolate was 150,267 base pairs in length, with 56.7% G + C content. Genetic and phylogenetic analysis showed that strain YM2019 (GenBank: MT063054) belonged to the ORF30 N752 genotype but displayed a high level of similarity with strain Ab4 (ORF30 D752, GenBank: AY665713) isolated in Britain. Fourteen unique amino acid mutations were found when comparing strain YM2019 with the reference strains Ab4 and V592 (ORF30 N752, GenBank: AY464052). Syrian hamsters infected with strain YM2019 exhibited severe respiratory and neurological clinical signs and died. Infection with strain YM2019 in Yili horses caused rhinopneumonitis, viremia, and neurological clinical signs such as hind limb lameness, prostration, and reduced movement. Here, we describe the features of an EHV-1 strain discovered in China, together with the complete genome sequence, and reveal that a nonneurovirulent strain (ORF30 N752) can also cause neurological signs in horses. The data will be useful in providing some reference for further research into the relationship between viral genotypes and pathogenicity.